Extended nodal radiotherapy for prostate cancer relapse guided with [11C]-choline PET/CT: ten-year results in patients enrolled in a prospective trial.
Extended nodal radiotherapy
PET guidance
Prostate cancer lymph node relapse
Simultaneous integrated boost
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
25 Sep 2023
25 Sep 2023
Historique:
received:
06
05
2023
accepted:
15
09
2023
medline:
25
9
2023
pubmed:
25
9
2023
entrez:
25
9
2023
Statut:
aheadofprint
Résumé
To report long-term outcomes of relapsed prostate cancer (PC) patients treated in a prospective single-arm study with extended-nodal radiotherapy (ENRT) and [11C]-choline positron emission tomography (PET)/computed tomography (CT)-guided simultaneous integrated boost (SIB) to positive lymph nodes (LNs). From 12/2009 to 04/2015, 60 PC patients with biochemical relapse and positive LNs only were treated in this study. ENRT at a median total dose (TD) = 51.8 Gy/28 fr and PET/CT-guided SIB to positive LNs at a median TD = 65.5 Gy was prescribed. Median PSA at relapse was 2.3 (interquartile range, IQR:1.3-4.0) ng/ml. Median number of positive LNs: 2 (range: 1-18). Androgen deprivation therapy (ADT) was prescribed for 48 patients for a median of 30.7 (IQR: 18.5-43.1) months. Median follow-up from the end of salvage treatment was 121.8 (IQR: 116.1, 130.9) months; 3-, 5-, and 10-year BRFS were 45.0%, 36.0%, and 24.0%, respectively; DMFS: 67.9%, 57.2%, and 45.2%; CRFS: 62.9%, 53.9%, and 42.0%; and OS: 88.2%, 76.3%, and 47.9%, respectively. Castration resistance (p < 0.0001) and ≥ 6 positive LN (p = 0.0024) significantly influenced OS at multivariate analysis. Castration resistance (p < 0.0001 for both) influenced DMFS and CRFS in multivariate analysis. In PC relapsed patients treated with ENRT and [11C]-choline-PET/CT-guided SIB for positive LNs, with 10-year follow-up, a median Kaplan-Meier estimate CRFS of 67 months and OS of 110 months were obtained. These highly favorable results should be confirmed in a prospective, randomized trial.
Identifiants
pubmed: 37747578
doi: 10.1007/s00259-023-06445-4
pii: 10.1007/s00259-023-06445-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Cheng L, Zincke H, Blute ML, Bergstrahl EJ, Scherer B, Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer. 2001;91(1):66–73.
doi: 10.1002/1097-0142(20010101)91:1<66::AID-CNCR9>3.0.CO;2-P
pubmed: 11148561
Moschini M, Sharma V, Zattoni F, et al. Natural history of clinical recurrence patterns of lymph node–positive prostate cancer after radical prostatectomy. Eur Urol. 2016;69(1):135–42.
doi: 10.1016/j.eururo.2015.03.036
pubmed: 25865061
Coen JJ, Zietman AL, Thakral H, Shipley WU. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol. 2002;20:3199–205.
doi: 10.1200/JCO.2002.01.086
pubmed: 12149291
Francini E, Gray KP, Xie W, et al. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate. 2018;78(12):889–95.
doi: 10.1002/pros.23645
pubmed: 29707790
pmcid: 6171350
Rigatti P, Suardi N, Briganti A, et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C] choline postron emission tomography/computed tomography. Eur Urol. 2011;60:935–43.
doi: 10.1016/j.eururo.2011.07.060
pubmed: 21840116
Jereczek-Fossa BA, Fariselli L, Beltramo G, et al. Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother Oncol. 2009;93:14–7.
doi: 10.1016/j.radonc.2009.04.001
pubmed: 19409636
Fodor A, Ingrosso A, Ceci F, et al. Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row: nodal oligorecurrent prostate cancer. World J Urol. 2019;37(12):2607–13.
doi: 10.1007/s00345-018-2322-7
pubmed: 29752513
Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36:446–53.
doi: 10.1200/JCO.2017.75.4853
pubmed: 29240541
Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6:650–9.
doi: 10.1001/jamaoncol.2020.0147
pubmed: 32215577
pmcid: 7225913
Deek MP, Van der Eecken K, Sutera P, et al. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol. 2022;40(29):3377–82.
doi: 10.1200/JCO.22.00644
pubmed: 36001857
De Bleser E, Jereczek-Fossa BA, Pasquier D, et al. Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy. Eur Urol. 2019;76(6):732–9.
doi: 10.1016/j.eururo.2019.07.009
pubmed: 31331782
Umbehr MH, Muntener M, Hany T, Sulser T, Bachmann LM. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013;64(1):106–17.
doi: 10.1016/j.eururo.2013.04.019
pubmed: 23628493
Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70(6):926–37.
doi: 10.1016/j.eururo.2016.06.021
pubmed: 27363387
Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208–16.
doi: 10.1016/S0140-6736(20)30314-7
pubmed: 32209449
le Guevelou J, Achard V, Mainta I, et al. PET/CT-based salvage radiotherapy for recurrent prostate cancer after radical prostatectomy: impact on treatment management and future directions. Front Oncol. 2021;11:742093.
doi: 10.3389/fonc.2021.742093
pubmed: 34532294
pmcid: 8438304
Scattoni V, Picchio M, Suardi N, et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol. 2007;52:423–9.
doi: 10.1016/j.eururo.2007.03.032
pubmed: 17397992
Rinnab L, Mottaghy FM, Blumstein NM, et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int. 2007;100:786–93.
doi: 10.1111/j.1464-410X.2007.07083.x
pubmed: 17822459
Picchio M, Berardi G, Fodor A, et al. 11C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2014;41:1270–9.
pubmed: 24599378
Fodor A, Berardi G, Fiorino C, et al. Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer. BJU Int. 2017;119(3):406–13.
doi: 10.1111/bju.13510
pubmed: 27104782
Cozzarini C, Fiorino C, Deantoni C, et al. Higher-than-expected severe (Grade 3–4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur Urol. 2014;66(6):1024–30.
doi: 10.1016/j.eururo.2014.06.012
pubmed: 24985964
Pollack A, Karrison TG, Balogh AG, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022;399:1886–901.
doi: 10.1016/S0140-6736(21)01790-6
pubmed: 35569466
pmcid: 9819649
Di Muzio NG, Deantoni CL, Brombin C, et al. Ten year results of extensive nodal radiotherapy and moderately hypofractionated simultaneous integrated boost in unfavorable intermediate-, high-, and very high-risk prostate cancer. Cancers (Basel). 2021;13(19):4970.
doi: 10.3390/cancers13194970
pubmed: 34638454
Di Muzio N, Fodor A, Berardi G, et al. Lymph nodal metastases: diagnosis and treatment. Q J Nucl Med Mol Imaging. 2012;56(5):421–9.
pubmed: 23069921
Fodor A, Cozzarini C, Fiorino C, Di Muzio NG. Oligometastatic disease in prostate cancer, a continuously changing paradigm: patient selection and treatment strategy. Transl Canc Research. 2017;6(suppl.1):S112–6.
doi: 10.21037/tcr.2017.01.19
Tamihardja J, Zehner L, Hartrampf P, et al. Salvage nodal radiotherapy as metastasis-directed therapy for oligorecurrent prostate cancer detected by positron emission tomography shows favorable outcome in long-term follow-up. Cancers (Basel). 2022;14(15):3766.
doi: 10.3390/cancers14153766
pubmed: 35954430
Vaugier L, Palpacuer C, Rio E, Goineau A, Pasquier D, Buthaud X, et al. Early Toxicity of a phase 2 trial of combined salvage radiation therapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer (OLIGOPELVIS GETUG P07). Int J Radiat Oncol Biol Phys. 2019;103(5):1061–7.
doi: 10.1016/j.ijrobp.2018.12.020
pubmed: 30557672
De Bruycker A, Spiessens A, Dirix P, et al. PEACE V – salvage treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial. BMC Cancer. 2020;20:406.
doi: 10.1186/s12885-020-06911-4
pubmed: 32398040
pmcid: 7216526
Decaestecker K, De Meerleer G, Lambert B, et al. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol. 2014;9:135.
doi: 10.1186/1748-717X-9-135
pubmed: 24920079
pmcid: 4066290
Ceci F, Castellucci P, Mapelli P, Incerti E, Picchio M, Fanti S. Evaluation of prostate cancer with 11C-Choline PET/CT for treatment planning, response assessment, and prognosis. J Nucl Med. 2016;57:49S-54S.
doi: 10.2967/jnumed.115.170126
pubmed: 27694172
Fossati N, Scarcella S, Gandaglia G, et al. Underestimation of positron emission tomography/computerized tomography in assessing tumor burden in prostate cancer nodal recurrence: head-to-head comparison of 68Ga-PSMA and 11C-Choline in a large, multi-institutional series of extended salvage lymph node dissections. J Urol. 2020;204:296–302.
doi: 10.1097/JU.0000000000000800
pubmed: 32068488
Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46.
doi: 10.1056/NEJMoa1503747
pubmed: 26244877
pmcid: 4562797
Kyriakopoulos CE, Chen Y-H, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080–7.
doi: 10.1200/JCO.2017.75.3657
pubmed: 29384722
pmcid: 5891129
Fizazi K, Tran NP, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686–700.
doi: 10.1016/S1470-2045(19)30082-8
pubmed: 30987939
Armstrong AJ, Szmulewitz RZ, Petrylak DP. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974–86.
doi: 10.1200/JCO.19.00799
pubmed: 31329516
pmcid: 6839905
Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121–31.
doi: 10.1056/NEJMoa1903835
pubmed: 31157964
Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13–24.
doi: 10.1056/NEJMoa1903307
pubmed: 31150574
Ingrosso G, Detti B, Fodor A, et al. Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy. Clin Transl Oncol. 2021;23:1577–84.
doi: 10.1007/s12094-021-02553-5
pubmed: 33495981
Valeriani M, Detti B, Fodor A, et al. Radiotherapy at oligoprogression for metastatic castration-resistant prostate cancer patients: a multi-institutional analysis. Radiol Med. 2022;127(1):108–16.
doi: 10.1007/s11547-021-01424-x
pubmed: 34748151